Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Patients Get Advice on How to Deal With Cancer-Related Fatigue

November 1, 1998
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 11
Volume 7
Issue 11

NEW YORK--Fatigue related to cancer or its treatment does not go away after a good night’s rest, and may last a month or longer. In the cancer setting, there may be many reasons for chronic fatigue, Lois Almadrones, RN, MPA, clinical research associate, Memorial Sloan-Kettering Cancer Center, said at a Cancer Care teleconference for cancer patients.

NEW YORK--Fatigue related to cancer or its treatment does not go away after a good night’s rest, and may last a month or longer. In the cancer setting, there may be many reasons for chronic fatigue, Lois Almadrones, RN, MPA, clinical research associate, Memorial Sloan-Kettering Cancer Center, said at a Cancer Care teleconference for cancer patients.

Ms. Almadrones gave a vivid description of what cancer-related chronic fatigue is like: "You’re exhausted. It’s a big effort to do anything. You have no ambition. Your mood might change so that if you’re usually talkative, you don’t want to talk. A usually bubbly person is miserable. You can’t concentrate. You may be so run down, you don’t feel like putting your clothes on. Everything sort of has a cloud hanging over it. There is a constant sense of working against gravity."

She reminded her audience that even a small medical procedure can take its toll. "Maybe it was a bone marrow aspiration or the taking of blood or a small biopsy that didn’t require general anesthesia," she said. "But you still had to come into the hospital. You still had to have some kind of local anesthetic or mild sedation. And if you had tissue removed for a biopsy, that caused damage."

Ms. Almadrones noted that virtually all patients who have radiation treatments report fatigue, and that radiation of the large bones in the upper legs, pelvis, and lower abdomen is known to cause the greatest fatigue.

The increased activity of showing up for regular medical treatments, and sometimes having to get up earlier than usual for the appointments, adds to the debilitating effects of treatment, and so does trying to maintain one’s precancer schedule of activities. The result may be chronic fatigue. "Your body is telling you that you really need to stop and make priorities about how to spend your day," Ms. Almadrones said.

Not getting a good night’s sleep only adds to the fatigue, and there are many reasons why cancer patients cannot sleep. Ms. Almadrones advised patients to "make sure that any pain medication you take when you go to bed is long acting. If your sleep problems are due to gastro-intestinal symptoms, perhaps the medication for the GI symptoms can be taken closer to bedtime. If you have been told to drink two quarts of liquid a day and urinary frequency is interfering with your sleep, try drinking the liquid by 6 pm."

Sleeping pills are no panacea, she warned. "Although it helps you to get sleep, it leaves you groggy and it’s not the same as natural sleep. If you can, wean yourself off it."

Avoid Anxiety Before Bedtime

Engaging in activities that raise one’s anxiety level before going to bed does not help either, she said. Someone who is worried about money should not work on their checkbook before going to bed, for example. Rather, people should continue to observe the sleep rituals that worked for them before their diagnosis, like taking a warm bath or reading a magazine before retiring or taking a walk in the evening, she said.

Just because a health care provider fails to inquire about a patient’s energy level is no reason for a patient not to bring it up, Ms. Almadrones said. "If you’re feeling fatigued, you definitely need to talk about it with your doctor or nurse on your next visit," she said.

She also noted several things that patients can do to help assess the causes of their fatigue. Keeping a daily journal of when one feels tired or energetic will help tease out some of the causative factors, as well as some of the anxious thoughts that may be interfering with sleep. Discovering the ups and down of energy can also help patients schedule activities so that they are less draining.

Proper nutrition and taking lots of fluids are also key and so is getting adequate rest throughout the day. Ms. Almadrones encourages patients to take short naps. She also encourages them to detach themselves from any personal problems that family members are having. "They can be an emotional drain. You need to conserve your energy for your own body and use it to cope with your own problems," she said.

Articles in this issue

Vinorelbine/Cisplatin Improves Survival In Advanced NSCLC
Centers Selected for STAR, Study of Tamoxifen and Raloxifene
HDC/PBSC for Advanced Breast Cancer Debated
New Programs Aim to Improve Home Care Services
Breast Cancer Patients Sought for Study of Premature Menopause
Study Update Shows Improved Survival With Anastrozole
New Colon Cancer Mouse Model First to Mimic Human Disease
Best Use of Breast Cancer Genetics Presents Clinical Challenge
Families Share Pleasure and Pain at The March
Panel Lists 13 Areas for Emphasis in NCI Breast Cancer Research
NCI Urged to Seize Opportunity for Prostate Cancer Research
Trends in the Epidemiology of Breast Cancer Are Encouraging
New Technology Allows Intravenous Injection of Busulfan
Tracking Case Rate Contracts for Stem Cell Transplants
Brachytherapy for Prostate Cancer Not Just Another Gimmick
Recent Videos
4 experts are featured in this series.
4 experts are featured in this series.
1 expert is featured in this series.
7 experts are featured in this series.
7 experts are featured in this series.
5 experts are featured in this series
Related Content
Advertisement

Among 35 patients with ovarian cancer treated with an antibody-based combination, the overall response rate was 23%, with a clinical benefit rate of 31%.

Botensilimab/Balstilimab Exhibits Meaningful Activity in Ovarian Cancer

Roman Fabbricatore
December 24th 2025
Article

Among 35 patients with ovarian cancer treated with an antibody-based combination, the overall response rate was 23%, with a clinical benefit rate of 31%.


Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Daniel C. McFarland, DO;Michelle Riba, MD
December 22nd 2025
Podcast

Daniel C. McFarland, DO; and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.


Data from the phase 3 MANUEVER trial support the approval of pimicotinib for patients in China with symptomatic tenosynovial giant cell tumors.

Pimicotinib Earns Approval in China for Tenosynovial Giant Cell Tumors

Russ Conroy
December 23rd 2025
Article

Data from the phase 3 MANUEVER trial support the approval of pimicotinib for patients in China with symptomatic tenosynovial giant cell tumors.


Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia

Krina K. Patel, MD, MSc;Manali Kamdar, MD;Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
December 15th 2025
Podcast

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.


Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.

Breast Cancer Data Affirm Aromatase Inhibitors as Optimal Endocrine Therapy

Andrea Eleazar, MHS
December 23rd 2025
Article

Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.


A total of 33% of patients with advanced prostate cancer receiving the combination therapy remained progression-free per PSA after 1 year of treatment.

Lu 177 Plus Immunotherapy Displays Responses in Prostate Cancer

Roman Fabbricatore
December 23rd 2025
Article

A total of 33% of patients with advanced prostate cancer receiving the combination therapy remained progression-free per PSA after 1 year of treatment.

Related Content
Advertisement

Among 35 patients with ovarian cancer treated with an antibody-based combination, the overall response rate was 23%, with a clinical benefit rate of 31%.

Botensilimab/Balstilimab Exhibits Meaningful Activity in Ovarian Cancer

Roman Fabbricatore
December 24th 2025
Article

Among 35 patients with ovarian cancer treated with an antibody-based combination, the overall response rate was 23%, with a clinical benefit rate of 31%.


Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Daniel C. McFarland, DO;Michelle Riba, MD
December 22nd 2025
Podcast

Daniel C. McFarland, DO; and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.


Data from the phase 3 MANUEVER trial support the approval of pimicotinib for patients in China with symptomatic tenosynovial giant cell tumors.

Pimicotinib Earns Approval in China for Tenosynovial Giant Cell Tumors

Russ Conroy
December 23rd 2025
Article

Data from the phase 3 MANUEVER trial support the approval of pimicotinib for patients in China with symptomatic tenosynovial giant cell tumors.


Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia

Krina K. Patel, MD, MSc;Manali Kamdar, MD;Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
December 15th 2025
Podcast

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.


Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.

Breast Cancer Data Affirm Aromatase Inhibitors as Optimal Endocrine Therapy

Andrea Eleazar, MHS
December 23rd 2025
Article

Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.


A total of 33% of patients with advanced prostate cancer receiving the combination therapy remained progression-free per PSA after 1 year of treatment.

Lu 177 Plus Immunotherapy Displays Responses in Prostate Cancer

Roman Fabbricatore
December 23rd 2025
Article

A total of 33% of patients with advanced prostate cancer receiving the combination therapy remained progression-free per PSA after 1 year of treatment.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.